Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments

Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide, diagnosed as muscle invasive in 25% of cases. Although several studies have demonstrated an overall 5% absolute survival benefit at 5 years with cisplatin-based combination neoadjuvant treatment, administration of ch...

Full description

Bibliographic Details
Main Authors: Giandomenico Roviello, Martina Catalano, Raffaella Santi, Matteo Santoni, Ilaria Camilla Galli, Andrea Amorosi, Wojciech Polom, Ugo De Giorgi, Gabriella Nesi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
muscle-invasive bladder cancer
neoadjuvant chemotherapy
immunotherapy
combined therapy
biomarkers
molecular subtypes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.912699/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.912699/full

Similar Items